Power Law company profile

Kailera Therapeutics

Biotech & Life Sciences · Waltham, United States · Founded 2024 · IPO 2026 Unicorn

A clinical-stage biopharma company advancing a diverse therapeutic pipeline aimed at delivering innovative treatments for obesity and related conditions

Valuation

$2.70B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

14 investors on Kailera Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

Lyra Capital

Bain Capital Life Sciences

Atlas Venture

RTW Investments

Series B+ 10 investors entered at this stage

Surveyor Capital

Qatar Investment Authority

T. Rowe Price

Perseverance Capital Management

Janus Henderson Investors

CPP Investments

Sirona Capital

Royalty Pharma

Invus

Bain Capital Private Equity

Global footprint

Where Kailera Therapeutics has talent and traffic

Workforce by country

🇺🇸 United States · Waltham HQ

Book a demo for the full country breakdown

Web traffic by country

12K monthly visits
across markets

🇺🇸 United States94.2%

🇮🇳 India6.7%

Top 2 markets shown

Market sentiment

What the market is saying about Kailera Therapeutics

An AI-synthesized read of the highest-engagement posts about Kailera Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kailera Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles